Literature DB >> 10122539

Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities.

R J Labelle1, J E Hurley.   

Abstract

Cost-utility analysis is increasingly being advocated as a tool for helping to establish funding priorities among programs and services in the health-care sector. As currently conducted, however, cost-utility analysis is problematic as a basis for achieving allocative efficiency because it excludes externalities. The exclusion of externalities may bias program ranking in unpredictable ways, leading to a non-optimal allocation of resources. Consideration of externalities also raises a number of distributional issues for the evaluation of health services and highlights the important of developing economic evaluation methods that are consistent with the conceptual basis for allocating resources.

Mesh:

Year:  1992        PMID: 10122539     DOI: 10.1016/0167-6296(92)90003-j

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  10 in total

Review 1.  Willingness to pay and the valuation of programmes for the prevention and control of influenza.

Authors:  S Birch; A Gafni; B O'Brien
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 2.  On individual preferences and aggregation in economic evaluation in healthcare.

Authors:  B Liljas; B Lindgren
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

4.  Assessing the benefits of health care: how far should we go?

Authors:  M Ryan; P Shackley
Journal:  Qual Health Care       Date:  1995-09

5.  Justice and the allocation of healthcare resources: should indirect, non-health effects count?

Authors:  Kasper Lippert-Rasmussen; Sigurd Lauridsen
Journal:  Med Health Care Philos       Date:  2010-08

6.  Alternatives to the QALY measure for economic evaluations.

Authors:  A Gafni
Journal:  Support Care Cancer       Date:  1997-03       Impact factor: 3.603

7.  Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England.

Authors:  Sandy Tubeuf; Eirini-Christina Saloniki; David Cottrell
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

8.  Tentative guidelines for using clinical and economic evaluations revisited.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

9.  QALYs and carers.

Authors:  Hareth Al-Janabi; Terry N Flynn; Joanna Coast
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

10.  A Framework for Including Family Health Spillovers in Economic Evaluation.

Authors:  Hareth Al-Janabi; Job van Exel; Werner Brouwer; Joanna Coast
Journal:  Med Decis Making       Date:  2015-09-16       Impact factor: 2.583

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.